Company Plans to Allocate Funds for Investigation into Methods in Genomics to Predict Multiple Myeloma Patient Response to Therapeutic Treatments
BUFFALO, N.Y., May 28, 2013 /PRNewswire/ — Empire Genomics, LLC (www.empiregenomics.com) has been awarded a Phase I SBIR Grant by the National Institute of Health/National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma (MM). This is the first SBIR grant Empire Genomics has been awarded and it will be funded through October 2013. The Company plans to use these funds to further develop its licensed technology to investigate methods in genomics to predict MM patient response to therapeutic treatments.
"Providing clinical tests that help physicians and patients better understand ideal treatments is critically important to disease management and lowering cost of healthcare," said Anthony Johnson, President & CEO of Empire Genomics. "We are excited to continue working on this assay and with pharmaceutical firms who are developing treatments for MM as we think it will be a useful resource to accelerate clinical trials and ultimately approvals."
This SBIR funding is further validation of the Empire licensed technology, the need for companion testing in this disease area and fills a void in the early-stage funding required to develop innovative molecular diagnostics.
About Empire Genomics
Empire Genomics LLC is a firm in the field of molecular genomic testing specializing in oncology. The company offers a wide range of best-in-class services that are used to detect genomic changes. The firm is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and determining treatment for diseases.
Contact:
Sonya Stutts
716-856-3873